Evidence map›Paper›PMID 38506376›Full record

ArticleMolecular carcinogenesis2024

Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis.

Ram Raj Prasad, Neha Mishra, Rama Kant, Jennifer T Fox, Robert H Shoemaker, Chapla Agarwal, Komal Raina, Rajesh Agarwal

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular carcinogenesis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Ram Raj PrasadDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Neha MishraDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Rama KantDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Jennifer T FoxChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Robert H ShoemakerChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Chapla AgarwalDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Komal RainaDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0003-0371-1070
Rajesh AgarwalDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-9455-0235
University of Colorado Anschutz Medical Campus · USNational Cancer Institute · USSouth Dakota State University · USUniversity of Colorado Cancer Center · US

Funding

CANCER CHEMOPREVENTION BY SILYMARINR01CA064514 · NCI · UNIVERSITY OF COLORADO DENVER · PI AGARWAL, RAJESH · 2000 to 2004
$1.2M
Kevin and Lorie Haarberg Funds for Cancer ResearchNCI HHS N2612015000381NCI NIH HHS R01 CA064514
6 · The paper itself

Abstract

Recent preclinical studies have shown that the intake of nonsteroidal anti-inflammatory drugs (NSAIDs) aspirin and naproxen could be an effective intervention strategy against TMPRSS2-ERG fusion-driven prostate tumorigenesis. Herein, as a follow-up mechanistic study, employing TMPRSS2-ERG (fusion) positive tumors and plasma from TMPRSS2-ERG. Pten

Indexed as

Anti-Inflammatory Agents, Non-SteroidalAspirinCarcinogenesisNaproxenOncogene FusionProstateProstatic NeoplasmsSerine EndopeptidasesTranscriptional Regulator ERGAnimalsCytokinesInflammationMaleMiceNeoplasms, ExperimentalOncogene ProteinsAnti-Inflammatory Agents, Non-SteroidalAspirinCytokinesERG protein, mouseNaproxenOncogene ProteinsPTEN PhosphohydrolasePten protein, mouseSerine EndopeptidasesTMPRSS2 protein, mouseTranscriptional Regulator ERGaspirincytokinesnaproxenNSAIDprostate cancerTMPRSS2‐ERG fusion

Identifiers

PMID38506376
PMCPMC11096027
OpenAlexW4393002857

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.